Health Care [ 9/12 ] | Pharmaceuticals [ 55/74 ]
NASDAQ | Common Stock
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; KYNMOBI a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 3, 25 | -0.16 Decreased by -46.09% | -0.13 Decreased by -21.28% |
| Nov 4, 24 | -0.13 Decreased by -333.33% | -0.13 |
| Aug 6, 24 | -0.03 Increased by +70.00% | -0.12 Increased by +75.00% |
| May 7, 24 | -0.17 Decreased by -41.67% | -0.08 Decreased by -112.50% |
| Mar 5, 24 | -0.11 Increased by +52.17% | -0.08 Decreased by -37.50% |
| Nov 6, 23 | -0.03 Increased by +86.96% | -0.11 Increased by +72.73% |
| Aug 7, 23 | -0.10 Increased by +72.22% | -0.12 Increased by +16.67% |
| May 2, 23 | -0.12 Increased by +62.50% | -0.19 Increased by +36.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 11.87 M Decreased by -10.14% | -17.05 M Decreased by -110.27% | Decreased by -143.72% Decreased by -134.00% |
| Sep 30, 24 | 13.54 M Increased by +4.15% | -11.51 M Decreased by -465.55% | Decreased by -84.99% Decreased by -443.00% |
| Jun 30, 24 | 20.10 M Increased by +51.79% | -2.75 M Increased by +52.61% | Decreased by -13.66% Increased by +68.78% |
| Mar 31, 24 | 12.05 M Increased by +8.25% | -12.83 M Decreased by -166.45% | Decreased by -106.43% Decreased by -161.38% |
| Dec 31, 23 | 13.21 M Increased by +23.63% | -8.11 M Increased by +55.31% | Decreased by -61.42% Increased by +63.85% |
| Sep 30, 23 | 13.00 M Increased by +13.43% | -2.04 M Increased by +83.77% | Decreased by -15.65% Increased by +85.69% |
| Jun 30, 23 | 13.24 M Decreased by -0.18% | -5.79 M Increased by +70.81% | Decreased by -43.74% Increased by +70.76% |
| Mar 31, 23 | 11.13 M Decreased by -9.26% | 19.31 M Increased by +215.59% | Increased by +173.40% Increased by +227.38% |